Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years

Phase 2Thykamine™Positive

AI Analysis

Summary

Devonian Health Group received Health Canada authorization to initiate a Phase II/III clinical trial of Thykamine™ for mild-to-moderate atopic dermatitis in pediatric patients aged 3 months to 17 years. The primary objective is to evaluate efficacy compared to placebo after 12 weeks of twice-daily treatment.

Clinical Trial Data

Phase

Phase II/III

Outcome Details

Health Canada authorization received to initiate Phase II/III pediatric clinical trial

Importance:6/10

Sentiment:

0.70

pediatricatopic dermatitisHealth Canada authorizationclinical trial initiation

Related Companies

$HIT

Read the original article

Published by PR Newswire Clinical Trials on July 21, 2026 12:45 PM

Read Original